PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Smoke & Salt is an award-winning, critically acclaimed restaurant that combines the idea for contemporary dining with ancient food storage methods. It is the first restaurant from Smoke & Salt Hospitality Group Ltd and has won many awards including The Cateys ‘Best Newcomer’ restaurant, a 5-star review from Time Out, and it was put 6th on the ‘Top 100 restaurants in London that you have to try’ list. The funds will be used to secure the restaurant site, buy the equipment, fund the fit-out and working capital for the company.
days to go:
Expired
investment:
£154,225
Poppy’s Picnic produces fresh raw dog food, handmade in the heart of Wiltshire, using quality local ingredients. Within a year of going online in Oct 16, it grew sales from £7k-£50k pm and started exporting to Hong Kong. Funds will be used to launch a cat food range and expand its dog food offering
days to go:
Expired
investment:
£577,180
Garbanzo Snacks is a profitable businesses, currently selling their chickpeas with a sprinkling of flavour in 725 Holland and Barrett stores. They use 100% chickpeas with minimal processing, this keeps the products as pure and unadulterated as possible.
days to go:
Expired
investment:
Withheld
Creating alcoholic beverages for the health-conscious consumer. SkinnyBrands produces 'better-for-you' alternatives for those looking to reduce the number of calories they consume, have gluten intolerances, or prefer to live a healthy and actively lifestyle but still love drinking beer.
In 2016/17, turnover was £445k and the company is now expecting a YoY increase of 211%. This will result in a turnover of £1.4m. SkinnyBrands's monetisation strategy involves selling their products through retailers worldwide via multiple distribution channels. Due to the business's rapid growth, this investment round will allow the company to make key hires in key markets such as the UK, USA and Australia, as well establish further distribution rights and stockists to sell their products.
days to go:
Expired
investment:
£437,599
Specilaing in making a wide variety of award-winning pies and pastry products for the public. Eat Square's 2017 funding round has resulted in their turnover more than doubling in 2018. This growth has led to Eat Square expanding their business and begin to sell franchises to market their goods. Production and capacity have also increased and products that are vegan and gluten-free are being produced. This funding round will see the business sell up to 14 franchises by the end of 2019 to buy their pies.
days to go:
Expired
investment:
£34,019
